Impact of DPP4 inhibitor saxagliptin on body weight of patients with type 2 diabetes: a clinical observation

被引：0
|
作者：
Zhang, Rui [1 ]
Zheng, Hongting [1 ]
Xu, Qiang Tong Jing [1 ]
Wang, Hui [1 ]
机构：
[1] Third Mil Med Univ, Xinqiao Hosp, Dept Endocrinol, Chongqing, Peoples R China
来源：
DIABETES-METABOLISM RESEARCH AND REVIEWS | 2016年 / 32卷 / SUPP 2期
关键词：
DPP4; inhibitor; weight; type; 2; diabetes;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
392067
引用
收藏
页码：40 / 41
页数：2
相关论文
共 50 条
  • [1] Clinical audit of patients using DPP4 inhibitors in longstanding type 2 diabetes
    Kumar, K. V. S. Hari
    Gupta, A. K.
    DIABETES & METABOLIC SYNDROME-CLINICAL RESEARCH & REVIEWS, 2015, 9 (04) : 277 - 279
  • [2] Durability of glycaemic control with dapagliflozin, an SGLT2 inhibitor, compared with saxagliptin, a DPP4 inhibitor, in patients with inadequately controlled type 2 diabetes
    Bailey, Clifford J.
    Del Prato, Stefano
    Wei, Cheryl
    Reyner, Daniel
    Saraiva, Gabriela
    DIABETES OBESITY & METABOLISM, 2019, 21 (11) : 2564 - 2569
  • [3] Safety and Efficacy of DPP4 Inhibitor and Basal Insulin in Type 2 Diabetes: An Updated Review and Challenging Clinical Scenarios
    Gomez-Peralta, Fernando
    Abreu, Cristina
    Gomez-Rodriguez, Sara
    Barranco, Rafael J.
    Umpierrez, Guillermo E.
    DIABETES THERAPY, 2018, 9 (05) : 1775 - 1789
  • [4] Saxagliptin: a new DPP-4 inhibitor for the treatment of type 2 diabetes mellitus
    Tahrani, Abd A.
    Piya, Milan K.
    Barnett, Anthony H.
    ADVANCES IN THERAPY, 2009, 26 (03) : 249 - 262
  • [5] Saxagliptin: a new DPP-4 inhibitor for the treatment of type 2 diabetes mellitus
    Abd A. Tahrani
    Milan K. Piya
    Anthony H. Barnett
    Advances in Therapy, 2009, 26 : 249 - 262
  • [6] Saxagliptin: A Selective DPP-4 Inhibitor for the Treatment of Type 2 Diabetes Mellitus
    Shubrook, Jay
    Colucci, Randall
    Guo, Aili
    Schwartz, Frank
    CLINICAL MEDICINE INSIGHTS-ENDOCRINOLOGY AND DIABETES, 2011, 4 : 1 - 12
  • [7] Effects of DPP4 Inhibitor in Platelet Reactivity and Other Cardiac Risk Markers in Patients with Type 2 Diabetes and Acute Myocardial Infarction
    Rizzo Genestreti, Paulo R.
    Furtado, Remo H. M.
    Salsoso, Rocio
    Dalcoquio, Talia F.
    Franci, Andre
    Menezes, Fernando R.
    Caporrino, Cesar
    Ferrari, Aline G.
    Nakashima, Carlos A. K.
    Scanavini Filho, Marco A.
    Lima, Felipe G.
    Giraldez, Roberto R. C., V
    Baracioli, Luciano M.
    Nicolau, Jose C.
    JOURNAL OF CLINICAL MEDICINE, 2022, 11 (19)
  • [8] Polyarthropathy in type 2 diabetes patients treated with DPP4 inhibitors
    Saito, Tatsuhiko
    Ohnuma, Kei
    Suzuki, Hiroshi
    Dang, Nam H.
    Hatano, Ryou
    Ninomiya, Hiroki
    Morimoto, Chikao
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2013, 102 (01) : E8 - E12
  • [9] Saxagliptin: a new dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes
    Deacon, Carolyn F.
    Holst, Jens J.
    ADVANCES IN THERAPY, 2009, 26 (05) : 488 - 499
  • [10] A comparison of effects of DPP-4 inhibitor and SGLT2 inhibitor on lipid profile in patients with type 2 diabetes
    Cha, Seon-Ah
    Park, Yong-Moon
    Yun, Jae-Seung
    Lim, Tae-Seok
    Song, Ki-Ho
    Yoo, Ki-Dong
    Ahn, Yu-Bae
    Ko, Seung-Hyun
    LIPIDS IN HEALTH AND DISEASE, 2017, 16 : 1 - 8
12345